Cited by 131PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record.

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Drew, Y., de Jonge, M., Hong, S.H., Park, Y.H., Wolfer, A., Brown, J., Ferguson, M., Gore, M.E., Alvarez, R.H., Gresty, C., Angell, H., Meyer, K., Learoyd, M., Tang, M., Lanasa, M., Herbolsheimer, P., Domchek, S.M.·2018·Gynecologic Oncology

DOI 10.1016/j.ygyno.2018.04.555

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2018.04.555

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Treatment of epithelial ovarian cancer
Kuroki, L. M., & Guntupalli, S. R. (2020) · BMJ · doi:10.1136/bmj.m3773 · Cited by 904
Exploring and comparing adverse events between PARP inhibitors
Lafargue, C. J., Molin, G. Z. D., Sood, A. K., & Coleman, R. L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30786-1 · Cited by 496
The Immunoscore: Colon Cancer and Beyond
Angell, H. K., Bruni, D., Barrett, J. C., Herbst, R., & Galon, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1851 · Cited by 399
Self-citation
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
Yang, C. Q., Xia, B.-R., Zhang, Z.-C., Zhang, Y., Lou, G., & Jin, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577869 · Cited by 358
“The phase I/II basket MEDIOLA trial demonstrated that olaparib in combination with an anti–PDL1 antibody, durvalumab, for the treatment of germline BRCA 1/ 2 mutations that were platinum-sensitive resulted in relapse of ovarian cancer (116).”
Background
PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant Cancers
Pilie, P. G., Gay, C. M., Byers, L. A., O’Connor, M. J., & Yap, T. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0968 · Cited by 343
Development of PARP and immune-checkpoint inhibitor combinations
Stewart, R. A., Pilié, P. G., & Yap, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2652 · Cited by 239
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 245
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
Liu, J. F., Herold, C. I., Gray, K. P., Penson, R. T., Horowitz, N. S., Konstantinopoulos, P. A., Castro, C. M., Hill, S. J., Curtis, J. D., Luo, W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3343 · Cited by 225
Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study
Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0056 · Cited by 220
PARP inhibitors in ovarian cancer
Franzese, E., Centonze, S., Diana, A., Carlino, F., Guerrera, L. P., Napoli, M. D., Vita, F. D., Pignata, S., Ciardiello, F., & Orditura, M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.002 · Cited by 220
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Gourley, C., Balmañà, J., Ledermann, J. A., Serra, V., Dent, R. A., Loibl, S., Pujade-Lauraine, É., & Boulton, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02050 · Cited by 195
PARP Inhibition in Cancer: An Update on Clinical Development
Sachdev, E., Tabatabai, R., Roy, V. Y., Rimel, B. J., & Mita, M. M. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00680-2 · Cited by 190
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Yap, T. A., Plummer, R., Azad, N. S., & Helleday, T. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238473 · Cited by 178
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00570 · Cited by 179
PARP inhibitors: enhancing efficacy through rational combinations
Bhamidipati, D., Haro-Silerio, J. I., Yap, T. A., & Ngoi, N. Y. L. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02326-7 · Cited by 183
Ovarian Cancer Immunotherapy: Turning up the Heat
Ghisoni, E., Imbimbo, M., Zimmermann, S., & Valabrega, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122927 · Cited by 162
Prospects for combining immune checkpoint blockade with PARP inhibition
Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
Boussios, S., Abson, C., Moschetta, M., Rassy, E., Karathanasi, A., Bhat, T., Ghumman, F. I. A., Sheriff, M., & Pavlidis, N. A. (2020) · Drugs in R&D · doi:10.1007/s40268-020-00301-8 · Cited by 142
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
Boussios, S., Karihtala, P., Moschetta, M., Karathanasi, A., Sadauskaite, A., Rassy, E., & Pavlidis, N. A. (2019) · Diagnostics · doi:10.3390/diagnostics9030087 · Cited by 129
New strategies in ovarian cancer treatment
Lee, J., Minasian, L. M., & Kohn, E. C. (2019) · Cancer · doi:10.1002/cncr.32544 · Cited by 124
Immunotherapy in Ovarian Cancer: Are We There Yet?
Kandalaft, L. E., Odunsi, K. O., & Coukos, G. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00508 · Cited by 126
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
Zimmer, A. S., Nichols, E. H., Cimino‐Mathews, A., Peer, C. J., Cao, L., Lee, M.-J., Kohn, E. C., Annunziata, C. M., Lipkowitz, S., Trepel, J. B., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0680-3 · Cited by 115
PARP Inhibitors in Cancer Diagnosis and Therapy
Chan, C. Y., Tan, K. V., & Cornelissen, B. T. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2766 · Cited by 109
“Olaparib þ durvalumab þ bevacizumab I/II MEDIOLA Advanced or metastatic solid tumor, irrespective of gBRCA1/2 status BRACAnalysis or myChoice assay (Myriad Genetics), HRD score undetermined NCT02734004 Active, not recruiting (50)”
Background
Targeting the immune microenvironment for ovarian cancer therapy
Blanc‐Durand, F., Xian, L. C. W., & Tan, D. S. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1328651 · Cited by 115
Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
Borella, F., Ghisoni, E., Giannone, G., Cosma, S. D., Benedetto, C., Valabrega, G., & Katsaros, D. (2020) · Diagnostics · doi:10.3390/diagnostics10030146 · Cited by 95
Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms
Jain, A., Barge, A., & Parris, C. N. (2024) · Oncogene · doi:10.1038/s41388-024-03227-6 · Cited by 104
Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer
Lee, E. K., & Konstantinopoulos, P. A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.06.004 · Cited by 89
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
Madariaga, A., Bowering, V. L., Ahrari, S., Oza, A. M., & Lheureux, S. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001288 · Cited by 86
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Drew, Y., Kim, J., Penson, R. T., O’Malley, D. M., Parkinson, C., Roxburgh, P., Plummer, R., Im, S., Imbimbo, M., Ferguson, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2249 · Cited by 93
Self-citation
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
Maiorano, B. A., Maiorano, M. F. P., Lorusso, D., & Maiello, E. (2021) · Cancers · doi:10.3390/cancers13174438 · Cited by 84
“Since BRCA mutation and HRD have been proposed to correlate with platinum sensitivity in contemporary deficient nucleotide excision repair, the co-administration of PARPis and ICIs in PS-ROC could result in higher ORR and survival rates [29-31].”
BackgroundInfluential
Role of Immunotherapy in Breast Cancer
Jacob, S. L., Huppert, L. A., & Rugo, H. S. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00483 · Cited by 81
Current Ovarian Cancer Maintenance Strategies and Promising New Developments
Gogineni, V., Morand, S. M., Staats, H., Royfman, R., Devanaboyina, M., Einloth, K. R., Dever, D., Stanbery, L., Aaron, P. A., Manning, L., et al. (2020) · Journal of Cancer · doi:10.7150/jca.49406 · Cited by 78
Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches
Palaia, I., Tomao, F., Sassu, C. M., Musacchio, L., & Panici, P. B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s205950 · Cited by 84
Wise Management of Ovarian Cancer: On the Cutting Edge
Boussios, S., Mikropoulos, C., Samartzis, E. P., Karihtala, P., Moschetta, M., Sheriff, M., Karathanasi, A., Sadauskaite, A., Rassy, E., & Pavlidis, N. A. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10020041 · Cited by 74
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
Madariaga, A., Lheureux, S., & Oza, A. M. (2019) · Cancers · doi:10.3390/cancers11030416 · Cited by 73
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
Wu, Z., Cui, P., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Chen, S., Huang, Z., et al. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/1179554921996288 · Cited by 72
The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers
Zhu, L., Liu, J., Chen, J., & Zhou, Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01218-8 · Cited by 71
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations
Veneris, J. T., Matulonis, U. A., Liu, J. F., & Konstantinopoulos, P. A. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.09.021 · Cited by 62
Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes
Ardighieri, L., Missale, F., Bugatti, M., Gatta, L. B., Pezzali, I., Monti, M., Gottardi, S., Zanotti, L., Bignotti, E., Ravaggi, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690201 · Cited by 63
“However, the recent combination of ICIs and PARPi provided better results (11, 47).”
Background
PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer
Post, C., Westermann, A. M., Bosse, T., Creutzberg, C. L., & Kroep, J. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102973 · Cited by 64
“Five patients discontinued olaparib and three discontinued durvalumab due to an adverse event (Drew et al., 2018, 2019).”
Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications
Bergholz, J. S., Wang, Q., Kabraji, S. K., & Zhao, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2300 · Cited by 58
MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors
Yang, B., Li, X., Fu, Y., Guo, E., Ye, Y., Li, F., Liu, S., Xiao, R., Liu, C., Lu, F., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2370 · Cited by 55
“gov) with four different PARPi/anti–PD-1/L1 combinations being tested: olaparib/ durvalumab (10, 11), niraparib/pembrolizumab (12), talazoparib/ avelumab (13, 14), and BGB-A317/BGB-290 (15).”
PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
Miller, R. E., El-Shakankery, K. H., & Lee, J. (2022) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2022.33.e44 · Cited by 55
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer
Kurnit, K. C., Coleman, R. L., & Westin, S. N. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0572-7 · Cited by 54
Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers
Liu, Y. L., & Zamarin, D. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0740-8 · Cited by 53
PARP Inhibitors in Breast and Ovarian Cancer
Wang, S. S. Y., Jie, Y. E., Cheng, S. W., Ling, G. L., & Heong, V. Y. M. (2023) · Cancers · doi:10.3390/cancers15082357 · Cited by 60
Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?
González-Martı́n, A., & Sánchez‐Lorenzo, L. (2019) · Cancer · doi:10.1002/cncr.32520 · Cited by 52
Driving Immune Responses in the Ovarian Tumor Microenvironment
Ning, F., Cole, C. B., & Annunziata, C. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.604084 · Cited by 51
Immune Therapy Opportunities in Ovarian Cancer
Kandalaft, L. E., Odunsi, K. O., & Coukos, G. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280539 · Cited by 52
Management and Treatment of Recurrent Epithelial Ovarian Cancer
Armbruster, S. D., Coleman, R. L., & Rauh‐Hain, J. A. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.005 · Cited by 50
Recent advancements in PARP inhibitors-based targeted cancer therapy
Zhou, P., Wang, J. L., Mishail, D., & Wang, C. (2020) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaa030 · Cited by 50
Therapeutic applications of PARP inhibitors in ovarian cancer
Xie, H., Wang, W., Xia, B., Jin, W., & Lou, G. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110204 · Cited by 47
PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
Musacchio, L., Caruso, G., Pisano, C., Cecere, S. C., Napoli, M. D., Attademo, L., Tambaro, R., Russo, D., Califano, D., Palaia, I., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s221001 · Cited by 48
Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment
Pirš, B., Škof, E., Smrkolj, V., & Smrkolj, Š. (2022) · Cancers · doi:10.3390/cancers14030631 · Cited by 47
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
Hunia, J., Gawalski, K., Szredzka, A., Suskiewicz, M. J., & Nowis, D. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1073797 · Cited by 45
Major clinical research advances in gynecologic cancer in 2018
Kim, M., Suh, D. H., Lee, K.-H., Eom, K., Toftdahl, N. G., Mirza, M. R., & Kim, J. (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e18 · Cited by 43
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
Vanacker, H., Harter, P., Labidi‐Galy, S. I., Banerjee, S. N., Oaknin, A., Lorusso, D., & Ray-Coquard, I. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102255 · Cited by 46
PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data
Moutafi, M. K., Economopoulou, P., Rimm, D. L., & Psyrri, A. K. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105292 · Cited by 45
Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints
Franzese, O., & Graziani, G. (2022) · Cancers · doi:10.3390/cancers14225633 · Cited by 44
Immunotherapy in breast cancer: current landscape and emerging trends
Ran, R., Chen, X., Yang, J., & Xu, B. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00667-y · Cited by 60
“Preclinical data indicated that PARP inhibitors may stimulate the host antitumor immune responses by generating neoantigens by DNA damage, upregulating interferon synthesis via the STING pathway, and augmenting PD-L1 expression [146, 147].”
Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy
Gou, R., Dong, H., & Lin, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118434 · Cited by 42
The DNA damage response network in the treatment of head and neck squamous cell carcinoma
Psyrri, A. K., Gkotzamanidou, M. A., Papaxoinis, G., Krikoni, L., Economopoulou, P., Kotsantis, I., Anastasiou, Μ., & Souliotis, V. L. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100075 · Cited by 43
Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications
Wanderley, C. W. S., Corrêa, T. S., Scaranti, M., Cunha, F. Q., & Barroso‐Sousa, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816642 · Cited by 40
Immunotherapy in Ovarian Cancer
Wang, W., Liu, J. R., & Zou, W. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.002 · Cited by 36
Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises
Pham, M. M., Ngoi, N. Y. L., Peng, G., Tan, D. S. P., & Yap, T. A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.05.004 · Cited by 38
Lactobacillus reuteri Releasing IL-22 (LR-IL-22) Facilitates Intestinal Radioprotection for Whole-Abdomen Irradiation (WAI) of Ovarian Cancer
Hamade, D. F., Espinal, A., Yu, J., Leibowitz, B. J., Fisher, R., Hou, W., Shields, D., van Pijkeren, J.-P., Mukherjee, A., Epperly, M. W., et al. (2022) · Radiation Research · doi:10.1667/rade-21-00224.1 · Cited by 36
Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer
Shen, K., Yang, L., Li, F., Zhang, F., Ding, L., Yang, J., Lu, J., Wang, N., & Wang, Y. (2021) · Current Drug Targets · doi:10.2174/1389450122666210617111304 · Cited by 34
Immunotherapy in ovarian cancer: fake news or the real deal?
Marth, C., Wieser, V. E., Tsibulak, I., & Zeimet, A. G. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2018-000011 · Cited by 35
Targeting DNA Damage Response and Repair Genes to Enhance Anticancer Immunotherapy: Rationale and Clinical Implication
Lamberti, G., Andrini, E., Sisi, M., Federico, A. D., & Ricciuti, B. (2020) · Future Oncology · doi:10.2217/fon-2020-0215 · Cited by 36
Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy
Khatoon, E., Parama, D., Kumar, A., Alqahtani, M. S., Abbas, M. A. E., Girisa, S., Sethi, G., & Kunnumakkara, A. B. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120827 · Cited by 34
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy
Schepisi, G., Casadei, C., Toma, I., Poti, G., Iaia, M. L., Farolfi, A., Conteduca, V., Lolli, C., Ravaglia, G., Brighi, N., et al. (2021) · Cancers · doi:10.3390/cancers13040840 · Cited by 31
DNA damage response and PD-1/PD-L1 pathway in ovarian cancer
Zhang, T., Zheng, S., Yang, L., Li, X., Wu, J., Sun, Y., & Liu, G. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103112 · Cited by 28
Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer
Gourley, C., & Bookman, M. A. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00337 · Cited by 25
PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
Lightfoot, M. D. S., Montemorano, L., & Bixel, K. L. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0873-4 · Cited by 25
Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
Soung, Y. H., & Chung, J. (2023) · Biomolecules · doi:10.3390/biom13101480 · Cited by 27
“Patients received 300 mg of Olaparib twice daily for 4 weeks, followed by a combination of Olaparib (300 mg) and Durvalumab (1.5 g) until tumor progression was observed [80].”
MethodInfluential
Effective antitumor activity of 5T4‐specific CAR‐T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo
Guo, C., Dong, E., Lai, Q., Zhou, S., Zhang, G., Wu, M., Yue, X., Tao, Y., Peng, Y., Ali, J., et al. (2020) · MedComm · doi:10.1002/mco2.34 · Cited by 24
Interleukin-6 Is a Crucial Factor in Shaping the Inflammatory Tumor Microenvironment in Ovarian Cancer and Determining Its Hot or Cold Nature with Diagnostic and Prognostic Utilities
Amer, H., Flanagan, K. L., Kampan, N. C., Itsiopoulos, C., Scott, C. L., Kartikasari, A. E. R., & Plebanski, M. (2025) · Cancers · doi:10.3390/cancers17101691 · Cited by 27
“For example, a Phase II trial led by Drew et al. explored the combination of durvalumab (an anti-PD1 agent) with Olaparib (a PARP inhibitor) in OC patients who were platinum-sensitive and had a BRCA mutation [202].”
Release of Interferon-β (IFN-β) from Probiotic Limosilactobacillus reuteri-IFN-β (LR-IFN-β) Mitigates Gastrointestinal Acute Radiation Syndrome (GI-ARS) following Whole Abdominal Irradiation
Hamade, D. F., Epperly, M. W., Fisher, R., Hou, W., Shields, D. S., van Pijkeren, J., Mukherjee, A., Yu, J., Leibowitz, B. J., Vlad, A., et al. (2023) · Cancers · doi:10.3390/cancers15061670 · Cited by 21
The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer
James, N. E., Woodman, M. F., DiSilvestro, P., & Ribeiro, J. R. (2020) · Cancers · doi:10.3390/cancers12082150 · Cited by 19
Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency
Li, W., Gao, L., Yi, X., Shi, S., Huang, J., Shi, L. M., Zhou, X., Wu, L., & Ying, J. (2023) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2023.02.004 · Cited by 19
An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION
Lee, J., Yi, J. Y., Kim, H. S., Lim, J. H.-J., Kim, S., Nam, B., Kim, H. S., Kim, J., Choi, C. H., Kim, B., et al. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz085 · Cited by 18
Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application
Xie, H., Wang, W., Qi, W.-C., Jin, W., & Xia, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661115 · Cited by 17
“In the phase II study involving 32 patients with germline BRCA1/2 mutant platinum-sensitive ovarian cancer, the disease control rate (DCR) at 12 weeks was 81%, and the objective response rate (ORR) was 63%, with acceptable toxicity (85).”
Background
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors
Lee, E. K., & Matulonis, U. A. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1773791 · Cited by 16
Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?
García-Martínez, E., Redondo, A., Piulats, J. M., Garzotto, A. A. R., & Casado, A. (2020) · Angiogenesis · doi:10.1007/s10456-020-09734-w · Cited by 15
Understanding genetic determinants of resistance to immune checkpoint blockers
Aspeslagh, S., Chabanon, R. M., Champiat, S., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.020 · Cited by 16
Strategies for the prevention or reversal of PARP inhibitor resistance
Mitri, Z. I., Goodyear, S. M., & Mills, G. B. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2393251 · Cited by 15
Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma
Huang, H.-J., Yang, L., Tung, H., Ku, F.-C., Wu, R., Tang, Y., Chang, W., Jung, S., Wang, C., Lin, C., et al. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.11.018 · Cited by 14
PARP inhibition in the ovarian cancer patient: Current approvals and future directions
Kurnit, K. C., Avila, M., Hinchcliff, E., Coleman, R. L., & Westin, S. N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107588 · Cited by 15
Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer
Flörkemeier, I., Hillmann, J. S., Weimer, J. P., Hildebrandt, J., Hedemann, N., Rogmans, C., Dempfle, A., Arnold, N., Clement, B., & Bauerschlag, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810503 · Cited by 13
PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?
Gay, C. M., & Byers, L. A. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.004 · Cited by 13
Immunotherapies in ovarian cancer
García-Martínez, E., & Fidalgo, J. A. P. (2020) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2020.02.002 · Cited by 13
BRCA mutations in pancreatic cancer and progress in their targeting
Alkassis, S., Yazdanpanah, O., & Philip, P. A. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1957462 · Cited by 13
Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance
Hinchcliff, E., Chelariu-Raicu, A., & Westin, S. N. (2020) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000678 · Cited by 12
Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?
Marques, C., da Silva, F. F., Sousa, I., & Nave, M. (2022) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003719 · Cited by 11
Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer
Martínez, A., Delord, J., Ayyoub, M., & Devaud, C. (2020) · Cancers · doi:10.3390/cancers12071761 · Cited by 11
Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors
Zhou, L., Wan, Y., Zhang, L., Meng, H., Yuan, L., Zhou, S., Cheng, W., & Jiang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116733 · Cited by 10
A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation
Wang, H., Mao, C., Li, N., Sun, L., Zheng, Y., & Xu, N. (2019) · Medicine · doi:10.1097/md.0000000000017443 · Cited by 10
Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research
Washington, C. R., Gunderson, C. C., & Moore, K. N. (2018) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000507 · Cited by 9
The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers
Xu, Q., Wen, Y., Huang, T., Li, H., Liu, X., Shi, S.-N., Gong, W., Mills, G. B., Ma, D., Gao, Q., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00814-x · Cited by 10

Authors: Drew, Y., de Jonge, M., Hong, S. H., Park, Y. H., Wolfer, A., Brown, J., Ferguson, M., Gore, M. E., Alvarez, R. H., Gresty, C., Angell, H., Meyer, K., Learoyd, M., Tang, M., Lanasa, M., Herbolsheimer, P., & Domchek, S. M.
Affiliations: Newcastle University (GB)
The Catholic University of Korea Seoul St. Mary's Hospital (KR)
Samsung Medical Center (KR)
Centre Hospitalier Universitaire Vaudois (CH)
Beatson West of Scotland Cancer Centre (GB)
NHS Tayside (GB)
Royal Marsden Hospital (GB)
AstraZeneca (United Kingdom) (GB)
AstraZeneca (United States) (US)
University of Pennsylvania (US)
Corresponding author: Drew, Y.
ORCID: Drew, Y.
Hong, S.H.
Park, Y.H.
Wolfer, A.
Ferguson, M.
Gresty, C.
Angell, H.
Meyer, K.
Learoyd, M.
Tang, M.
Domchek, S.M.
Venue: Gynecologic Oncology
Publisher: Elsevier BV
Published: 2018-06
Volume: 149
Pages: 246-247
ISSN: 0090-8258 (ISSN-L)
DOI: 10.1016/j.ygyno.2018.04.555
OpenAlex: W2811158315
Cited by: 131
References: 0
Citations by year: 2026: 2 · 2025: 7 · 2024: 4 · 2023: 14 · 2022: 12 · 2021: 19 · 2020: 37 · 2019: 30 · 2018: 6
FWCI: 8.70
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gynecologic Oncology (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: olaparib, durvalumab, germline BRCA mutation, platinum-sensitive recurrent ovarian cancer, PARP inhibitors, PD-L1 inhibitors, combination therapy, maintenance therapy, treatment efficacy and safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks